Molecular Templates, Inc. - Common Stock (MTEM)

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Directors, effective Apr. 22. He succeeds Allan Camaisa, who will continue as a Board member. Dr. Poma, a veteran biotech leader, brings over 30 years of experience, including roles at Molecular Templates (NASDAQ: MTEM), where he raised over $250 million and secured strategic partnerships with Takeda, Vertex, and BMS. As Calidi advances its systemic virotherapy platform and prepares for a dose-escalation trial of CLD-201 in solid tumors, the leadership change is expected to support the company’s transition into later-stage clinical development.

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board.

Molecular Templates, Inc. (NASDAQ: MTEM) is one of today’s top gainers. The company’s shares have moved 25.97% on the day to $2.33.